The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Neostigmine Methylsulfate
Neostigmine Methylsulfate · NEOSTIGMINE METHYLSULFATE 1 mg/mL · Injection, Solution · Intravenous · Fresenius Kabi USA, LLC
NDC 76045-0383-30 · 10 BLISTER PACK in 1 CARTON / 1 SYRINGE, GLASS in 1 BLISTER PACK / 3 mL in 1 SYRINGE, GLASS · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$150.00
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2025)
$5,854
431 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Fresenius Kabi USA, LLCUnited Statesanalysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA203629
- TE code
- AP
- Approval date
- Jan 8, 2015
- Patents / exclusivity
- None on file
Shortage history
- Planned discontinuation — Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10)Jan 12, 2026
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Neostigmine Methylsulfate (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Fresenius Kabi USA, LLC | NEOSTIGMINE METHYLSULFATE .5 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Fresenius Kabi USA, LLC | NEOSTIGMINE METHYLSULFATE 1 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Dr.Reddys Laboratories Inc | NEOSTIGMINE METHYLSULFATE 1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | NEOSTIGMINE METHYLSULFATE .5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | NEOSTIGMINE METHYLSULFATE 1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Neostigmine Methylsulfate — NDC 76045-0383-30," retrieved September 3, 2026, https://drugdashboards.com/drug/76045038330.
Free to cite with attribution — see how the data is put together.